NKGen Biotech, Inc.

Graf Acquisition Corp. IV, a blank-check company that traded on Nasdaq under the ticker GFOR and was sponsored by Graf Acquisition LLC, completed its business combination with NKGen Biotech, Inc. in September 2023, as reflected in an 8-K filed on September 29, 2023. Graf Acquisition Corp. IV conducted its initial public offering in 2022, targeting the healthcare and life sciences sector. NKGen Biotech is a clinical-stage biopharmaceutical company developing natural killer cell immunotherapies, with lead programs focused on neurodegenerative conditions including Alzheimer's disease. Following the closing, the combined company traded on Nasdaq under the ticker NKGN. Sign up at SpacDesk for full filing history, deal analytics, and real-time data across the SPAC market.